Horizon Therapeutics: Q3 Earnings Insights

Shares of Horizon Therapeutics HZNP decreased 2.6% in pre-market trading after the company reported Q3 results.

Quarterly Results

Earnings per share were up 171.88% over the past year to $1.74, which beat the estimate of $0.94.

Revenue of $636,427,000 up by 89.71% year over year, which beat the estimate of $517,680,000.

Outlook

The upcoming fiscal year's revenue expected to be between $2,120,000,000 and $2,140,000,000.

Details Of The Call

Date: Nov 02, 2020

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/fkvfuayc

Price Action

52-week high: $86.67

Company's 52-week low was at $23.81

Price action over last quarter: Up 1.08%

Company Profile

Horizon Therapeutics PLC is a specialty and generic drug manufacturing company. The company is focused on researching, developing and commercializing medicines that address critical needs for people impacted by rare and rheumatic diseases. The company has two reportable segments: orphan and rheumatology segment and the inflammation segment. It markets medicines in the areas of orphan diseases, rheumatology and inflammation division. The majority of revenue is generated in the United States.